摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-6,6'dimethoxybiphenyl-2,2'-bisphosphine

中文名称
——
中文别名
——
英文名称
(R)-6,6'dimethoxybiphenyl-2,2'-bisphosphine
英文别名
[3-Methoxy-2-(2-methoxy-6-phosphanylphenyl)phenyl]phosphane
(R)-6,6'dimethoxybiphenyl-2,2'-bisphosphine化学式
CAS
——
化学式
C14H16O2P2
mdl
——
分子量
278.227
InChiKey
GTTDREDMUVHXSB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-碘苯甲酸(R)-6,6'dimethoxybiphenyl-2,2'-bisphosphine1,1'-双(二苯基膦)二茂铁 、 palladium diacetate 、 N,N-二异丙基乙胺 作用下, 以 乙腈 为溶剂, 以70%的产率得到(R)-6,6'-dimethoxy-P2,P2,P2',P2'-tetrakis-[4-(carbonyloxy)phenyl]biphenyl-2,2'-bisphosphine
    参考文献:
    名称:
    Efficient Route to Atropisomeric Ligands – Application to the Synthesis of MeOBIPHEP Analogues
    摘要:
    A highly efficient Pd-catalyzed P-C coupling reaction of easily accessible atropisomeric bisphosphane is described in the presence of various electron-poor aromatic iodides. The reactions are conducted in the presence of a Pd(II)/dppf catalyst in acetonitrile at 80 degrees C. The reaction conditions are compatible with several electron-withdrawing groups such as esters, cyano, chloro, and trifluoromethyl groups and lead to atropisomeric MeOBIPHEP derivatives in good to excellent yields and high enantiomeric purities.
    DOI:
    10.1021/ol2011874
点击查看最新优质反应信息

文献信息

  • Asymmetric hydrogenation of 1,1,1- trifluoroacetone
    申请人:Puentener Kurt
    公开号:US20080027249A1
    公开(公告)日:2008-01-31
    The invention relates to the preparation of enantiomerically pure (S)-1,1,1-trifluoro-2-propanol by asymmetric hydrogenation of 1,1,1-trifluoroacetone which process comprises hydrogenating 1,1,1-trifluoroacetone in the presence of a ruthenium phosphine complex catalyst represented by formula Ru(E)(E)(L)(A) wherein E, E′ are both chloro or E is hydrogen and E′ is BH 4 ; L is a chiral diphosphine ligand; and A is an optionally chiral diamine wherein hydrogenation occurs in the presence of a weak base, with or without an additive, when E and E′ are both chloro or b) in the absence of a base and an additive when E and E′ are hydrogen and BH 4 .
    该发明涉及通过不对称氢化1,1,1-三乙酮来制备对映纯的(S)-1,1,1-三-2-丙醇的方法,该过程包括在存在以Ru(E)(E)(L)(A)为表示的膦配合物催化剂下氢化1,1,1-三乙酮,其中E,E′均为或E为氢,E′为BH4;L为手性双膦配体;A为可选择手性二胺,在E和E′均为或b)时,在弱碱的存在下进行氢化,有无添加剂均可,当E和E′均为氢和 时,在无碱和添加剂的情况下进行氢化。
  • PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO
    申请人:Dolle Roland E.
    公开号:US20150045556A1
    公开(公告)日:2015-02-12
    Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
    该专利介绍了一种制备周围性阿片受体拮抗剂化合物及其中间体的新工艺。该工艺所制备的化合物可以作为mu、kappa和delta阿片受体的拮抗剂,因此可以用于治疗胃肠运动障碍,并预防周围性阿片类药物引起的副作用。该工艺可能提供更高的产率、化学或立体化学纯度、中间体和最终产品易于制备和分离,以及更具工业应用性的反应条件和可操作性。
  • METHOD FOR PRODUCING OPTICALLY ACTIVE FLUORINE-CONTAINING OXETEN
    申请人:Tokyo Institute of Technology
    公开号:EP2644605B1
    公开(公告)日:2016-04-06
  • NOVEL COMPOUND, NOVEL LIGAND, NOVEL TRANSITION METAL COMPLEXES, AND CATALYSTS CONSISTING OF NOVEL TRANSITION METAL COMPLEXES
    申请人:National University Corporation Okayama University
    公开号:EP2676963B1
    公开(公告)日:2016-08-24
  • SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES
    申请人:Firmenich SA
    公开号:EP2970067B1
    公开(公告)日:2017-08-16
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫